Chemoimmunotherapy with Krestin in acute leukemia. 1981

T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori

The purpose of this study was to determine if immunotherapy with Krestin can prolong the durations of complete remission and survival. The patients were placed at random in the chemotherapy and chemoimmunotherapy groups. The median durations of complete remission and survival were longer in the chemoimmunotherapy group than in the chemotherapy group. The complete remission rate of the second induction was higher in the chemoimmunotherapy group than in the chemotherapy group. The cell-mediated immunity was somewhat enhanced in the chemoimmunotherapy group, while it was not enhanced in the chemotherapy group. These results suggested that Krestin administration for maintenance therapy was useful for prolongation of the durations of remission and survival time in patients with acute leukemia.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
October 1981, Cancer,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
May 1978, Nihon rinsho. Japanese journal of clinical medicine,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
July 1977, Israel journal of medical sciences,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
January 2012, Blood reviews,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
January 1980, Cancer,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
March 1981, Cancer,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
January 1978, Neoplasma,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
January 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
October 1976, Cancer,
T Nagao, and M Komatsuda, and K Yamauchi, and H Nozaki, and K Watanabe, and S Arimori
January 1980, Sovetskaia meditsina,
Copied contents to your clipboard!